Amrutanjan Health Care Past Earnings Performance
Past criteria checks 4/6
Amrutanjan Health Care has been growing earnings at an average annual rate of 2.4%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 9.2% per year. Amrutanjan Health Care's return on equity is 16%, and it has net margins of 10.9%.
Key information
2.4%
Earnings growth rate
2.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 9.2% |
| Return on equity | 16.0% |
| Net Margin | 10.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Amrutanjan Health Care (NSE:AMRUTANJAN) Is Paying Out A Dividend Of ₹1.00
Nov 19
Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 31Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 17We Think You Should Be Aware Of Some Concerning Factors In Amrutanjan Health Care's (NSE:AMRUTANJAN) Earnings
May 31Pinning Down Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) P/E Is Difficult Right Now
May 03Amrutanjan Health Care (NSE:AMRUTANJAN) Has Affirmed Its Dividend Of ₹1.00
Feb 12Amrutanjan Health Care (NSE:AMRUTANJAN) Has Announced A Dividend Of ₹2.60
Sep 02Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 19Amrutanjan Health Care (NSE:AMRUTANJAN) Is Due To Pay A Dividend Of ₹2.60
Aug 05Amrutanjan Health Care (NSE:AMRUTANJAN) Has Announced A Dividend Of ₹1.00
Feb 17Amrutanjan Health Care (NSE:AMRUTANJAN) Will Pay A Dividend Of ₹1.00
Nov 08Amrutanjan Health Care (NSE:AMRUTANJAN) Will Pay A Dividend Of ₹2.60
Aug 18Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 30Should You Be Adding Amrutanjan Health Care (NSE:AMRUTANJAN) To Your Watchlist Today?
Apr 08Introducing Amrutanjan Health Care (NSE:AMRUTANJAN), The Stock That Zoomed 162% In The Last Five Years
Mar 11Trade Alert: The Non-Executive Independent Director Of Amrutanjan Health Care Limited (NSE:AMRUTANJAN), Govindan Raghavan, Has Just Spent ₹72k Buying A Few More Shares
Feb 24Is It Smart To Buy Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Before It Goes Ex-Dividend?
Feb 14Is Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) Latest Stock Performance A Reflection Of Its Financial Health?
Feb 12Is Amrutanjan Health Care Limited (NSE:AMRUTANJAN) A Smart Choice For Dividend Investors?
Jan 30
Is There More To The Story Than Amrutanjan Health Care's (NSE:AMRUTANJAN) Earnings Growth?
Jan 17Here's Why I Think Amrutanjan Health Care (NSE:AMRUTANJAN) Is An Interesting Stock
Jan 04What Type Of Shareholders Make Up Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) Share Registry?
Dec 22How Much is Amrutanjan Health Care's (NSE:AMRUTANJAN) CEO Getting Paid?
Dec 09If You Had Bought Amrutanjan Health Care (NSE:AMRUTANJAN) Stock Five Years Ago, You Could Pocket A 106% Gain Today
Nov 26Here's What We Like About Amrutanjan Health Care's (NSE:AMRUTANJAN) Upcoming Dividend
Nov 14Why Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Should Be In Your Dividend Portfolio
Oct 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Amrutanjan Health Care Limited's NSE:AMRUTANJAN) Stock?
Oct 10I Ran A Stock Scan For Earnings Growth And Amrutanjan Health Care (NSE:AMRUTANJAN) Passed With Ease
Sep 22What Percentage Of Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Shares Do Insiders Own?
Sep 01With Amrutanjan Health Care Limited (NSE:AMRUTANJAN) It Looks Like You'll Get What You Pay For
Aug 11Have Insiders Been Selling Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Shares?
Jul 29Revenue & Expenses Breakdown
How Amrutanjan Health Care makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 4,378 | 475 | 537 | 0 |
| 30 Jun 24 | 4,271 | 426 | 1,048 | 0 |
| 31 Mar 24 | 4,214 | 450 | 484 | 0 |
| 31 Dec 23 | 3,946 | 440 | 398 | 0 |
| 30 Sep 23 | 3,753 | 373 | 461 | 0 |
| 30 Jun 23 | 3,865 | 432 | 973 | 0 |
| 31 Mar 23 | 3,798 | 398 | 493 | 0 |
| 31 Dec 22 | 3,860 | 418 | 500 | 0 |
| 30 Sep 22 | 3,990 | 517 | 494 | 0 |
| 30 Jun 22 | 3,986 | 588 | 1,037 | 0 |
| 31 Mar 22 | 4,059 | 672 | 505 | 0 |
| 31 Dec 21 | 3,935 | 627 | 1,211 | 0 |
| 30 Sep 21 | 3,829 | 631 | 1,159 | 0 |
| 30 Jun 21 | 3,644 | 668 | 966 | 0 |
| 31 Mar 21 | 3,330 | 612 | 497 | 0 |
| 31 Dec 20 | 2,984 | 589 | 763 | 0 |
| 30 Sep 20 | 2,811 | 474 | 777 | 0 |
| 30 Jun 20 | 2,635 | 322 | 809 | 0 |
| 31 Mar 20 | 2,617 | 251 | 834 | 0 |
| 31 Dec 19 | 2,876 | 314 | 833 | 0 |
| 30 Sep 19 | 2,751 | 274 | 804 | 0 |
| 30 Jun 19 | 2,621 | 257 | 750 | 0 |
| 31 Mar 19 | 2,535 | 250 | 756 | 0 |
| 31 Dec 18 | 2,406 | 158 | 785 | 0 |
| 30 Sep 18 | 2,335 | 168 | 762 | 0 |
| 30 Jun 18 | 2,288 | 201 | 710 | 0 |
| 31 Mar 18 | 2,203 | 200 | 671 | 0 |
| 31 Dec 17 | 2,247 | 165 | 722 | 0 |
| 31 Mar 17 | 2,240 | 211 | 710 | 0 |
| 31 Mar 16 | 1,867 | 206 | 505 | 0 |
| 31 Mar 15 | 1,666 | 149 | 468 | 0 |
| 31 Mar 14 | 1,417 | 124 | 508 | 1 |
Quality Earnings: AMRUTANJAN has a high level of non-cash earnings.
Growing Profit Margin: AMRUTANJAN's current net profit margins (10.9%) are higher than last year (9.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AMRUTANJAN's earnings have grown by 2.4% per year over the past 5 years.
Accelerating Growth: AMRUTANJAN's earnings growth over the past year (27.5%) exceeds its 5-year average (2.4% per year).
Earnings vs Industry: AMRUTANJAN earnings growth over the past year (27.5%) exceeded the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: AMRUTANJAN's Return on Equity (16%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 02:53 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Amrutanjan Health Care Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pranoy Kurian | Centrum Broking (Non-Insti) Clients |
| Harini V. | FirstCall Research |